![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014
December 01, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present at three events during the month of December.
Oppenheimer 25th...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 21, 2014 08:00 ET
|
Merrimack Pharmaceuticals
Clinical data from Phase 1 studies of MM-398 and MM-151 presented
First public presentation of MM-131, a novel bi-specific antibody targeting the c-Met signaling pathway
BARCELONA, Spain, Nov....
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
November 19, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal...
![Dr. Vivian S. Lee](http://www.globenewswire.com/en/Attachment/LogoDisplay/318215?filename=318215.jpg&size=2)
Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
November 17, 2014 08:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium
November 13, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 10, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
November 06, 2014 08:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
November 05, 2014 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call
November 03, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2014 Investor Conference Call and webcast...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer
September 30, 2014 08:00 ET
|
Merrimack Pharmaceuticals
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2...